Company: LENZ
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001628280-25-016813
Chunk: 2

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: POS AM
Chunk 2
---
 S-1, as amended by Amendment No. 1 to Form S-1 filed on April 9, 2024 (File No. 333-278393) (the “Initial Registration Statement”) with the Securities and Exchange Commission (the “SEC”). The Initial Registration Statement was declared effective by the SEC on April 10, 2024 to initially register for resale by the selling securityholders identified in the prospectus of an aggregate of 1,297,411 shares of common stock, which are held or may be held by the selling securityholders named in the prospectus, as amended, contained in the Initial Registration Statement.

This Post-Effective Amendment No. 1 to Form S-1 on Form S-3 (“Post-Effective Amendment No. 1”) is being filed by the Company (i) to convert the Initial Registration Statement into a registration statement on Form S-3, (ii) to include updated information regarding the selling securityholders named in the prospectus, including a reduction in the number of shares of common stock being offered by the selling securityholders to 1,022,809 shares, and (iii) to update certain other information based on recent developments. No additional securities are being registered hereunder. All applicable registration fees were paid at the time of the original filing of the Initial Registration Statement.

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

#### 1,022,809 Shares of Common Stock
This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 1,022,809 shares of common stock, par value $0.00001 per share (the “Common Stock”) issued in a private placement (the “PIPE Financing”). This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions.

We are registering the resale of these securities to satisfy certain registration rights we have granted. We will not receive any of the proceeds from the sale of the securities by the selling securityholders. We will pay the expenses associated with registering the sales by the selling securityholders, as described in more detail in